Astellas Korea – Jeong Hai-Do, President
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
Astellas Pharma Korea, Inc. is the Korean subsidiary of a leading global pharmaceutical company with outstanding R&D capabilities and a worldwide network.
Astellas has contributed to increasing the quality of life of customers by developing drugs to treat adult diseases and disorders such as urination disturbances common in men, frequent urination commonly in women, overactive bladder syndrome that causes frequent bathroom trips, as well as painful atopic dermatitis. The company also developed Gaster D, a gastroduodenal ulcer treatment drug, which has helped decrease the frequency of gastric ulcer surgery, and Prograf, and immunosuppression agent, which has improved the survival rate of organ transplant recipients.
Astellas Pharma Korea has been growing as a firm, taking pride in its contributions to customer quality of life, and provision of premium medicines in Korea, including Harnal, Vesicare, Prograf, and Protopic Ointment. It also a promising company in the mid-to-long term with many superb products awaiting further development, clinical testing, and launch. Astellas Pharma Korea does not aim to merely expand sales volume, but will continuously increase company value with the goal of maximizing added value for customers and thoseseeking better health, by establishing its Global Category Leader business model.
Contact details
6F 401 Hakdong-ro, Gangnam-gu, Seoul
+82 2 3448 0504
www.astellas.co.kr
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
You have recently been appointed as General Manager of Servier in South Korea, after coming from several years working in Europe. What perception did you have of the far-way Korean…
Since KRPIA’s creation in 1999, what would you say have been its main achievements in the South Korean pharmaceutical landscape? KRPIA’s foremost achievement during its existence has been its contribution…
What was the vision behind the creation of the Korea Drug Research Association and its main role in the pharmaceutical sector? Until the middle of the 1980s when Korea Drug…
Could you briefly introduce VGX International to our readers, and in particular explain its relation to US-based company VGX Pharmaceutical (VGXP)? The backbone of VGXP is the University of Pennsylvania…
You have been in S. Korea for a little over a year, following international assignments in Vietnam and Thailand. Besides the fact that this is a much bigger market, what…
You have been working in the CRM industry, particularly with pharmaceutical companies, for more then 10 years. Could you briefly introduce to our readers how the CRM industry has evolved…
Could you please give a brief presentation of Invest Korea to our readers? Invest Korea is the national investment promotion agency, responsible for attracting FDI into Korea. We have existed…
Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you…
What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in…
What are the origins of Lundbeck in Korea and your involvement in its establishment? I joined Lundbeck just before it was officially established in Korea in April 2002. We started…
Though you have recently been appointed as President of KRIBB, your history with the institute goes quite far back. Could you please briefly explain the role it plays within South…
See our Cookie Privacy Policy Here